Brad Herskowitz, MD

Brad Herskowitz, MD

Brad Herskowitz, MD

Brad Herskowitz, MD is a board-certified neurologist with just over 20 years of medical experience. He practices general neurology at The Neurology Group, a cutting-edge, research-driven medical practice in Miami that serves patients from communities across southeastern Florida.

Dr. Brad J. Herskowitz has special training in comprehensive stroke and Alzheimer’s Disease, concussion treatment, sleep disorder management, and migraine therapy. He’s also an expert in Botox® injection therapy for both cosmetic and neurological conditions.

Dr. Herskowitz has been a principal investigator in numerous clinical research trials, given many lectures on a wide range of topics in neurology, and published articles in several medical journals. He previously served as a Florida boxing ringside physician and is currently a team physician for the Miami Heat NBA basketball team. He’s also the Clinical Assistant Professor for the Department of Neurology at Florida International University Medical School.

After receiving his undergraduate degree from the University of Florida, Dr. Herskowitz obtained his medical degree from the University of Miami School of Medicine. He completed a two-year internal medicine residency at the University of Miami-Jackson Memorial Hospital before going on to complete a three-year neurology residency at Yale-New Haven Hospital, where he was chief resident.

Dr. Herskowitz a member of the American Academy of Neurology, the American Medical Association, and the American Society for Professional Ringside Physicians.

In addition to his office practice at The Neurology Group, Dr. Herskowitz is on staff at Baptist Health, West Kendall, Baptist South Miami Hospital, and Jackson South.

 

Specialties
Alzheimer’s Disease, Headaches/Migraines, Neurology

Board Certifications
American Board of Psychiatry and Neurology

Education 
August 1993 – May 1996 University of Miami School of Medicine, Coral Gables, FL
Medical Doctor

August 1988 – May 1992 University of Florida, Gainesville, FL
Bachelors of Science

Residency
July 2000 – June 2001 Yale-New Haven Hospital, New Haven, CT
Chief Resident in Neurology

July 1998 – June 2000 Yale-New Haven Hospital, New Haven, CT
Neurology Resident

August 1996 – June 1998 University of Miami-Jackson Memorial Hospital, Miami, FL
Residency in Internal Medicine

Memberships
2004 – Present American Society for Professional Ringside Physicians

2001 – Present American Academy of Neurology

2001 – Present American Medical Association

Awards & Accolades
July 1999 – June 2000 Resident of the Year Award, Yale University Department

June 2000 Recipient of American Academy of Neurology Annual Meeting Scholarship for Residents

Research & Clinical Trials
2009 JANSSEN Alzheimer Immunotherapy: A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer’s disease who Participated in Study ELN115727-301 or in Study ELN115727-302. (Protocol No.: ELN115727-351) CRO: PRA International

2009 Pfizer Inc.: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Tanezumab on Peripheral Nerve Function in Patients with Osteoarthritis. (A4091026)

2009 Sepracor Inc.: Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled By Current Antiepileptic Drugs. (Protocol No.: 093-045) CRO: Inc Research.

2009 Supernus Pharmaceuticals Inc.: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Adjunctive Therapy in Subjects with Refractory Partial Seizures due to Epilepsy on up to Two Concomitant Antiepileptic Medications. (Protocol No.: 804P301)

CRO: PAREXEL Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Two Concomitant Antiepileptic Medications. (Protocol No.: 804P302) CRO: PAREXEL

2008 Eisai Inc. and Pfizer Inc.: A 12-week, Multicenter, open-label study to evaluate the effectiveness and safety of donepezil hydrochloride (E2020) in subjects with mild to severe Alzheimer’s disease residing in an assisted living facility. (Protocol No.: E2020-A001-415) CRO: PAREXEL International.

2008 Elan Pharmaceutical Inc.: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB 001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E e4 Non-Carries. (Protocol No.: ELN115727-301) CRO: PRA International.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB 001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E e4 Carries. (Protocol No.: ELN115727-302) CRO: PRA International.

2008 Pfizer Inc.: A Phase 3, Multi-Center, Randomized, Double-Blind, Controlled Study of the Long-Term Analgesic Efficacy and Safety of Tanezumab Alone or in Combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) versus NSAIDs Alone in Patients with Osteoarthritis of the Knee or Hip. (Protocol No.: A4091025) CRO: PharmaNet, LLC.

2007 Johnson & Johnson: A Randomized – Withdrawal Phase III Study Evaluating the Safety and Efficacy of CG5503 Extended Release (ER) in Subjects with Painful Peripheral Neuropathy (DPN). Protocol No.: R331333-PAI-3015. CRO: INC Research.

2007 *UCB Pharma Inc.: A Multicenter, Double-Blind, Historical Control Randomized Conversion to Monotherapy with Keppra XR for Treatment of Partial Onset Seizures Study. (Protocol No.: N01280) CRO: PRA International. An Open-Label, Long-Term Follow-Up Study with Keppra XR for Treatment of Partial Onset Seizures. (Protocol No.: N01281) CRO: PRA International.

2007 *Biogen Idec: A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis. (Protocol No.: 109MS302) CRO: PRA International.

2007 Minster Research LTD.: Multi-Centre, Parallel Group, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Tolerability of Tonabersat in
the Prophylaxis of Migraine Headache and Open-Label Extension. (Protocol No.: TON/03/07-CLIN) CRO: PRA International.

2007 Bayer Healthcare Pharmaceutical: Success of Titration, Analgesics. And B.E.T.A. Nurse Support on Acceptance Rates in Early MS Treatment with Betaseron (START) with Betaseron Study): An Open-Label, Multicenter, Observational, Phase IV Study to Evaluate the Adherence to Treatment with 250mg (8MIU) IFNb-1b (Betaseron) Given Subcutaneous Every Other Day Over a period of up to 12 Months in Patients with a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis (RRMS) Within the past 12 months. (Protocol No.: 311501) CRO: INC Research.

2006 *GlaxoSmithKline: A 28 day, Polysomnographic and Subject Assessments of GW679769, 10 and 30mg, for the Treatment of Primary Insomnia: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial (Protocol No.: MAD103894) CRO: PPD, Inc.

2005 Fujisawa Healthcare Inc.: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase II Study to Evaluate the Safety and Efficacy of FK 962 in
Subjects with Mild to Moderate Alzheimer’s Disease (Protocol No.: 03-0-189) CRO: i3 Research

2005 Bristol-Myers Squibb: A Pilot Study to examine the effects of Clopidogrel compared to Placebo on markers of inflammation in subjects with Metabolic Syndrome who are receiving background therapy including low dose aspirin (Protocol No.: L 9842)

2005 Allergan: A Multicenter Study Evaluating the Efficacy and Safety of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patient with 15 or more Headaches per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group
Phase Followed by a 32-Week Open-Label Extension Phase. (Protocol No.:191622-079)

2005 Wyeth Pharmaceuticals Inc.: A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety Tolerability, and Efficacy Study of 3 Does of Lecozotan (SRA-333) SR in Outpatients with Mild to Moderate Alzheimer’s Disease with Donepezil as Active Control (Protocol No.: 3098B1-201-WW) A Multicenter, Randomized, Double-Blind, Long-Term Extension Study to Determine the Safety, Tolerability, and Preliminary Long-Term Efficacy of Lecozotan (SRA-333) SR in Patients with Mild to Moderate Alzheimer’s Disease (Protocol No.: 3098B1-202-WW) A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Saftey, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients with Mile do Moderate Alzheimer’s Disease Treated with Cholinesterase Inhibitor (Protocol No.: 3098B1-203-WW)

2005 AstraZeneca: A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (Oral Tablets 400mg to 800mg Daily in Divided Does) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Valproate) in Maintenance Treatment of Bipolar I Disorder in Adult Patients (Protocol No.: D1447C00126)

2005 AstraZeneca: A Multicenter, Double-Blind, Randomised –withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarte Sustained Release (SEROQUEL SR) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilisation Period (AMETHYST STUDY) Protocol No.: D1448C00005

2004 Saegis Pharmaceuticals Inc.: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of SGS742 in Subjects
with Mild to Moderate Alzheimer’s Disease. (Protocol No.: SGS724-CL02) CRO: INC Research.

2004 ethica Clinical Research Inc.: A Double-Blind Comparison of BOTOX (Botulinum Toxin Type A) and TOPAMAX for the Prophylactic Treatment of Chronic Migraine Headaches – Pilot Study

2003 Allan Herskowitz, M.D., F.A.C.P.: Evaluation of BOTOX (Botulinum Toxin Type A) in the Treatment of Patients with Neck Pain (Single-Center, Randomized, Double-Blind, Two-Arm, Concurrent Placebo Control)

2002 Allan Herskowitz, M.D., F.A.C.P.: Evaluation of BOTOX (Botulinum Toxin Type A) in the Treatment of Patients with Subacute Low Back Pain (Single-Center, Randomized, Double-Blind, Two-Arm, Concurrent Placebo Control)

Accepts New Patients
Yes

Languages
English, Spanish

Location
9090 SW 87th Court, Suite 200
Miami, FL 33176
(305) 596-2080

Hours
Monday and Friday
9:00 a.m. – 5:00 p.m.

Hospital Affiliations
Baptist Hospital
South Miami Hospital
West Kendall Baptist Hospital
Jackson South Community Hospital

 

Brad Herskowitz, MD is a neurologist located in Miami, Florida. You can contact his office at (305) 596-2080.</p